Trinity Biotech (TRIB) said Tuesday it has secured $5.5 million in additional liquidity through amended agreements with Perceptive Advisors, including cash and payment-in-kind interest.
As part of the agreement, Trinity has granted Perceptive 1.5 million additional warrants to buy its American depositary shares and repriced its existing warrants to $0.80 per ADS, Trinity added.
A $5 million deferred payment tied to its acquisition of Waveform Technologies assets was also extended to November 2025, increasing its financial flexibility, Trinity Biotech said.
The liquidity will support the company's transformation plan, including its World Health Organization-approved transition to offshore manufacturing for TrinScreen HIV and Uni-Gold HIV, Trinity Biotech said.
Trinity Biotech were up more than 10% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。